Dose Escalation and Remission (DEAR)

Ulcerative Colitis Clinical Trial

— DEAR  

Official title:

Test Treat Strategy to Prevent Ulcerative Colitis Relapse

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00652145
• Other study ID #: K24DK078228
• Secondary ID: K24DK078228
• Status: Completed
• Phase: Phase 4
• First received: April 1, 2008
• Last updated: May 4, 2015
• Start date: September 2008
• Est. completion date: January 2013

Study information

• Verified date: May 2015
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels <50µg/g stool will be observed for 48 weeks. All patients will have FCP concentration measured using a commercially available assay at enrollment, 6 weeks and 12 weeks. All patients with persistently elevated FCP will receive one or both of the following interventions: change in the mesalamine formulation to Lialda and/or increase in the dose of Lialda. Reduction in FCP levels below 50µg/g stool 6 weeks after randomization will be the primary outcome. The proportion of patients achieving this outcome will be compared between groups using Fisher's exact test. All randomized patients as well as those who were excluded from the randomized trial because of a low FCP concentration at baseline will be followed to week 48 to determine the rate of clinical relapse.

Description:

Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse. We performed an open-label, randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin (FC) in patients with quiescent UC.

We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores, FC >50 µg/g, and intake of no more than 3 g/day mesalamine. Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine (2.4 g/day) for 6 weeks; 52 participants were then randomly assigned (1:1) to a group that continued its current dose of mesalamine (controls, n = 26) or a group that increased its dose by 2.4 g/day for 6 weeks (n = 26). The primary outcome was continued remission with FC <50 µg/g. Secondary outcomes were continued remission with FC <100 µg/g or <200 µg/g (among patients with pre-randomization values above these levels).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 119
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Understand and sign the informed consent form.

2. Have documented ulcerative colitis on the basis of usual diagnostic criteria including clinical symptoms and findings from endoscopy, radiology studies, and histology.

3. Have a Simple Clinical Colitis Activity Index (SCCAI)55 score below 3 with no category value greater than 1 (Table 5).

4. Three or fewer bowel movements per 24 hours at the time of enrollment.

5. No visible blood in their bowel movements in the three days prior to enrollment.

6. Have either been on a stable dose of mesalamine medication (oral, rectal or a combination of oral and rectal, including sulfasalazine) or on no mesalamine medications for at least 4 weeks prior to enrollment.

7. Have been on either a stable dose of azathioprine, 6-mercaptopurine, or methotrexate or on none of these medications for at least 8 weeks prior to enrollment.

8. Have experienced at least one flare of ulcerative colitis in the 2 years prior to enrollment. A flare is defined as an increase in stool frequency, bleeding, urgency and/or abdominal discomfort sufficient to warrant a change in medication dose or addition of a new medication.

9. Most recently measured serum creatinine level in the preceding year less than 1.5 mg/dL.

Exclusion Criteria:

1. Age less than 18

2. Inability to speak and read English

3. Presence of an ostomy or prior total or subtotal colectomy

4. Current corticosteroid use or use within the two weeks prior to enrollment

5. Remission for less than 4 weeks prior to enrollment

6. Previous intolerance to mesalamine at doses greater than the current dose.

7. Use of rectally administered mesalamine or steroids within the 2 weeks prior to enrollment.

8. Currently taking more than 3.0 gm/day of mesalamine (oral or rectal). If on oral and rectal mesalamine, the combined dose is more than 3.0 gm/day.

9. Use of anti-TNFa therapies within the 8 weeks prior to enrollment and/or intent to use anti-TNFa therapies as maintenance therapy in the coming 12 weeks.

10. Pregnant or breast feeding women.

11. Use of an experimental therapy for ulcerative colitis in the 8 weeks prior to enrollment.

12. Any condition that the investigator feels will make completion of the study unlikely.

13. Use of cyclosporine in the two weeks prior to enrollment.

14. Moderate or severe abdominal tenderness on examination at time of enrollment.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• mesalamine
Increase dose by 2.4gm per day over baseline dose

Locations

Country	Name	City	State
United States	Atlanta Gastroenterology Associates	Atlanta	Georgia
United States	University of Maryland Medical Center	Baltimore	Maryland
United States	Chevy Chase Clinical Research	Chevy Chase	Maryland
United States	South Jersey Gastroenterology	Marlton	New Jersey
United States	Gastroenterology Group of Naples	Naples	Florida
United States	University of Pennsylvania - Presbyterian Medical Center	Philadelphia	Pennsylvania
United States	Minnesota Gastroenterology, P.A.	Plymouth	Minnesota
United States	Shafran Gastroenterology Center	Winter Park	Florida

Sponsors (3)

Lead Sponsor	Collaborator
James Lewis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Shire

Country where clinical trial is conducted

United States, 

References & Publications (1)

Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, Wolf D, Hardi R, Nessel L, Brensinger C, Gilroy E, Lewis JD; DEAR Investigators. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gast — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fecal Calprotectin Level <50µg/g		6 weeks after randomization	No
Secondary	Fecal Calprotectin Level <100 µg/g		at 6 weeks after randomization	No
Secondary	Fecal Calprotectin <200 µg/g		at 6 weeks after randomization	No